Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease—A multicenter, retrospective, observational study
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (2) , 236-241
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studiesThe Lancet, 2017
- Ulcerative colitisThe Lancet, 2017
- Crohn's diseaseThe Lancet, 2017
- Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel diseaseExpert Opinion on Biological Therapy, 2016
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND TrialGastroenterology, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006